Clinical trialNCT00002760CompletedPhase 3Interventional

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

SponsorAlliance for Clinical Trials in OncologyEnrollment260Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eric Small, MD
University of California, San Francisco
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsf Cancer Center and Cancer Research Institute
San Francisco, California, United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ketoconazole →Therapeutic hydrocortisone

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 1996
Primary completion: 31 Mar 2004
Completion: 30 Apr 2009
Last update posted: 28 Jun 2016
Registered enrollment: 260
Registry id: NCT00002760

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.